KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

CRISPR Therapeutics AG (CRSP) Profit After Tax (2016 - 2025)

CRISPR Therapeutics AG (CRSP) has disclosed Profit After Tax for 11 consecutive years, with -$130.6 million as the latest value for Q4 2025.

  • Quarterly Profit After Tax fell 250.07% to -$130.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$581.6 million through Dec 2025, down 58.8% year-over-year, with the annual reading at -$581.6 million for FY2025, 58.8% down from the prior year.
  • Profit After Tax hit -$130.6 million in Q4 2025 for CRISPR Therapeutics AG, down from -$106.4 million in the prior quarter.
  • In the past five years, Profit After Tax ranged from a high of $759.2 million in Q2 2021 to a low of -$208.5 million in Q2 2025.
  • Historically, Profit After Tax has averaged -$68.7 million across 5 years, with a median of -$114.9 million in 2021.
  • Biggest five-year swings in Profit After Tax: surged 1053.13% in 2021 and later tumbled 250.07% in 2025.
  • Year by year, Profit After Tax stood at -$141.2 million in 2021, then grew by 21.72% to -$110.6 million in 2022, then skyrocketed by 180.8% to $89.3 million in 2023, then plummeted by 141.76% to -$37.3 million in 2024, then crashed by 250.07% to -$130.6 million in 2025.
  • Business Quant data shows Profit After Tax for CRSP at -$130.6 million in Q4 2025, -$106.4 million in Q3 2025, and -$208.5 million in Q2 2025.